What You Ought to Know
- Analytical and scientific laboratory expertise big Agilent Technologies Inc. introduced that it has entered right into a definitive settlement to acquire digital pathology software program and AI firm Proscia®.
- Transaction monetary phrases: an all-cash acquisition valued at $240M in money at closing, plus as much as a further $30M contingent on attaining future operational and monetary efficiency milestones (complete potential deal worth of $270M).
- Closes the loop on a four-year industrial partnership: Agilent and Proscia initially entered right into a multi-year world distribution settlement in September 2022 to co-market an open digital diagnostic pathology ecosystem.
- Unifies an end-to-end precision medication triad: merges Agilent’s established portfolio of automated slide stainers, pathology instrumentation, diagnostic reagents, and companion diagnostics (CDx) with Proscia’s vendor-agnostic enterprise software program platform, Concentriq®, which serves as an operational orchestration layer throughout scanners, LIS networks, and AI algorithms.
Assembling the Full Pathology Stack
By buying Proscia, Agilent secures the lacking software program working system. As a substitute of promoting discrete devices and reagents, Agilent can now ship an end-to-end ecosystem: tissue preparation reagents, automated staining instrumentation, vendor-neutral whole-slide ingestion, and regulatory-cleared diagnostic software program.
Agilent and Proscia initially entered right into a multi-year world distribution settlement in September 2022 to co-develop and promote built-in diagnostic pathology workflows. Buying Proscia transitions an exterior industrial alliance into an owned mental property core.
Agilent is a major diagnostic companion for world pharma, co-developing FDA-approved companion diagnostic exams that decide affected person eligibility for focused most cancers immunotherapies. Integrating Concentriq offers Agilent a direct digital information conduit into 16 of the highest 20 biopharmas, creating an R&D suggestions loop that unites potential biomarker discovery with downstream scientific commercialization.
Transaction Economics & Goal Working Benchmarks
The acquisition brings a high-margin, recurring-revenue software program basis into Agilent’s diagnostic portfolio:
- Valuation A number of & Buy Value: Agilent is deploying $240M in money at closing plus as much as $30M in earnouts in opposition to Proscia’s trailing twelve months (TTM) income exceeding $18M —representing an upfront enterprise value-to-revenue a number of of roughly 13.3x (increasing to fifteen.0x together with full earnouts), reflecting excessive market demand for enterprise software program working layers in diagnostics.
- Industrial Scale and Penetration: Proscia’s platform—anchored by its flagship Concentriq® software program—is deployed throughout greater than 4,000 laboratories, hospital methods, and clinics throughout North America and Europe.
- High-Tier Biopharma Validation: Proscia software program at the moment helps translational analysis and trial operations for 16 of the highest 20 world pharmaceutical firms.
- Scientific Efficiency Benchmarks: Proscia earned 2026 Greatest in KLAS for Digital Pathology (securing the best vendor efficiency rating throughout each U.S. and European markets) and holds U.S. FDA 510(ok) clearance for major scientific analysis.
“Digital pathology is rapidly turning into the inspiration for pathology information technology, evaluation, and utility throughout biopharmaceutical analysis, scientific improvement, and diagnostics, and our acquisition of Proscia meaningfully expands our presence on this fast-growing market,” stated Padraig McDonnell, President and CEO of Agilent. “The acquisition establishes an Agilent platform for scientific intelligence in tissue-based precision medication, connecting information technology with AI-based interpretation in a workflow that helps biomarker analysis by means of routine scientific use. With Proscia’s main platform and proficient workforce, we might be higher outfitted to assist laboratories and biopharma prospects handle and derive insights from pathology information.”
